In the first quarter of 2008, Eckert & Ziegler Strahlen und Medizintechnik AG (ISIN DE 0005659700) will record extraordinary earnings amounting to EUR 7.3 million or EUR 2.34 per share. This can be attributed to the sale of the business with prostate cancer implants to the Belgian company International Brachytherapy SA in February and results from the difference between an extraordinary book profit amounting to EUR 14 million on the one hand and a series of related special amortizations and provisions amounting to EUR 6.7 million which the Executive Board of the Berlin company decided on at its meeting today.
As well as this special income, in the first quarter the isotope specialist from Pankow will also record a profit of EUR 0.6 million or EUR 0.19 per share arising from operational business, so a total of EUR 8 million or EUR 2.53 per share. Further details about the special income and the figures for the first quarter will be published with the I/2008 quarterly report on 6 May 2008 and one of the places where they can be viewed is on the company website www.ezag.de. Andreas Eckert, CEO of Eckert & Ziegler AG, is available to answer further questions in a telephone conference, held on 6 May 2008 at 10.15 a.m.
As well as this special income, in the first quarter the isotope specialist from Pankow will also record a profit of EUR 0.6 million or EUR 0.19 per share arising from operational business, so a total of EUR 8 million or EUR 2.53 per share. Further details about the special income and the figures for the first quarter will be published with the I/2008 quarterly report on 6 May 2008 and one of the places where they can be viewed is on the company website www.ezag.de. Andreas Eckert, CEO of Eckert & Ziegler AG, is available to answer further questions in a telephone conference, held on 6 May 2008 at 10.15 a.m.
